| Species |
Cynomolgus |
| Protein Construction |
| mFc (IgG2a) |
BDCA-2 (Tyr48-Ile212)
Accession # A0A2K5UWP4 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized BDCA-2 mFc Chimera, Cynomolgus at 0.5μg/ml (100μl/well) on the plate can bind AntiBDCA2 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
46.00 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
BDCA-2, BDCA-3, and BDCA-4. In blood, BDCA-2 and BDCA-4 are expressed on CD11c(-) CD123(bright) plasmacytoid dendritic cells, whereas BDCA-3 is expressed on small population of CD11c() CD123(-) dendritic cells. All three Ags are not detectable on a third blood dendritic cell population, which is CD1c() CD11c(bright) CD123(dim), or on any other cells in blood.BDCA-2 is completely down-regulated on plasmacytoid CD11c(-) CD123(bright) dendritic cells, BDCA-2 is rapidly internalized at 37 degrees C after mAb labeling. |
| Synonyms |
BDCA-2; BDCA2; CLECSF11; CLECSF7; DLEC; HECL; CLEC4C; CD303; CD303; DLEC; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
